<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131335</url>
  </required_header>
  <id_info>
    <org_study_id>265860</org_study_id>
    <nct_id>NCT04131335</nct_id>
  </id_info>
  <brief_title>Use of Prophylactic Lubricating Drops After Cataract Surgery</brief_title>
  <official_title>Patient Satisfaction and Dry Symptoms in NHS Patients Undergoing Routine Uncomplicated Cataract Surgery Treated With Prophylactic Phosphate-free, Preservative-free Lubricant Eye Drops. A Randomised Controlled Prospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>City, University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised controlled trial to assess the use of prophylactic lubricant eye-drops
      for 6 weeks following uncomplicated, routine cataract surgery to improve patient satisfaction
      and symptoms of dry eye, compared to controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On entry into the study patients will be randomized to receive either lubricant eye-drops
      (phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate
      with vitamins A and E (AEONTM Repair) to be administered four times a day for 6 weeks
      following surgery (in addition to the usual post-operative topical medications of
      Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex)
      four times a day for 4 weeks) or no additional lubricant drops in addition to the usual
      medications described above
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 14, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Satisfaction (CatPROM 5)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Validated patient satisfaction questionnaire are used. Specially designed and validated conversion tables are used to convert raw scores from questionnaires to Rasch calibrated measures.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-reported Health Outcome</measure>
    <time_frame>6 weeks</time_frame>
    <description>A validated self-reported health questionnaire is used where a descriptive and vertical Visual Analogue Scale (VAS) are used. The descriptive scale assesses 5 domains at three levels of difficulty (no / some / extreme problems). The VAS is used to to record patients' self-reported health on a scale from 0-100 (100/100 being excellent health, 0/100 being very poor health.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Symptoms (Speed II questinnaire)</measure>
    <time_frame>6 weeks</time_frame>
    <description>A validated questionnaire is used with a grading system to grade severity of dry eye . symptoms. Score out of 28. Higher the score, the more significant the dry eye symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cornea and Conjunctival Staining Scores</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Oxford Scale is used to grade staining of the conjunctiva and cornea. 0-5 (0 no staining, 5 significant staining).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer 1 test</measure>
    <time_frame>6 weeks</time_frame>
    <description>Evaluation of aqueous tear production. Score of more than 10mm is normal. Less than 10mm indicates aqueous tear deficiency .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Break up Time</measure>
    <time_frame>6 weeks</time_frame>
    <description>Score of more than 10 seconds is normal. Less than 10 seconds indicates tear evaporative eye disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cataract incision site and size</measure>
    <time_frame>6 weeks</time_frame>
    <description>Assess cataract incision size in relation to other tests and symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Dry Eye</condition>
  <condition>Cataract Surgery</condition>
  <condition>Patient Related Outcome Measures</condition>
  <condition>Patient Satisfaction</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental arm receives lubricant eye-drops (phosphate-free, preservative-free lubricant eye drops containing 0.15% Sodium Hyaluronate with vitamins A and E (AEONTM Repair) to be administered four times a day for 6 weeks following cataract surgery (in addition to the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control arm group receive the usual post-operative topical medications of Chloramphenicol 0.5 % eye drops for 1 week and topical dexamethasone 0.1% eyedrops (Maxidex) four times a day for 4 weeks after cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AEONTM Repair</intervention_name>
    <description>Lubricating eye drops</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine post-operative eye drops used.</intervention_name>
    <description>Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bilateral or unilateral cataracts requiring surgical intervention

          -  Age over 18 years

          -  Able to understand informed consent and the objectives of the trial

          -  Not pregnant, not breast feeding

          -  No previous eye surgery

        Exclusion Criteria:

          -  age-related macula degeneration

          -  glaucoma

          -  previous retinal vascular disorders

          -  previous retinal detachment or tear

          -  any neuro-ophthalmological condition

          -  any inherited retinal disorder or pathology

          -  previous strabismus surgery or record of amblyopia

          -  previous TIA, CVA or other vaso-occlusive disease

          -  already enrolled in another study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Khayam Naderi, MBBS BSc MA</last_name>
    <phone>020 7188 7188</phone>
    <phone_ext>84331</phone_ext>
    <email>khayam.naderi@gstt.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Thomas' Hospital NHS Trust London</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Dr Khayam Naderi, MBBS BSc MA</last_name>
      <phone>020 7188 7188</phone>
      <phone_ext>84331</phone_ext>
      <email>khayam.naderi@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Prof David O'Brart, FRCOphth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

